What Is Tremfya, and Why Does It Matter? Tremfya (guselkumab) is a lab-made, dual-acting antibody medication that reduces inflammation by targeting the interleukin-23 (IL-23) protein and blocking a ...

"For many patients, having a subcutaneous induction option is an important step forward—offering the flexibility of at-home administration after proper training without compromising efficacy," said ...

"Treatment with TREMFYA resulted in significant improvement in the chronic symptoms of ulcerative colitis, and importantly, normalization in the endoscopic appearance of the intestinal lining," said ...

How Does Tremfya Work for Crohn's Disease? Tremfya is a type of medicine called a monoclonal antibody. It works by targeting a protein in your body called interleukin-23 (IL-23). IL-23 is a cytokine ...

TREMFYA® offers the flexibility of self-administration from the start of treatment, building on the prior approval of subcutaneous induction in Crohn's disease TREMFYA® achieved significant rates of ...

Tremfya is the only IL-23 inhibitor with IV and SC induction options for treating Crohn disease. The Food and Drug Administration (FDA) has approved Tremfya ® (guselkumab) for the treatment of adults ...

HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and Drug Administration has approved a subcutaneous induction regimen of TREMFYA (guselkumab) for the treatment of adults with ...

With a fresh endorsement from the FDA, Johnson & Johnson has rounded out Tremfya’s presence in inflammatory bowel disease (IBD) and, in doing so, achieved a first for the IL-23 inhibitor drug class.

TREMFYA® is now approved for pediatric patients living with moderate to severe plaque psoriasis, who are candidates for systemic therapy or phototherapy, and active psoriatic arthritis in children six ...

Please provide your email address to receive an email when new articles are posted on . The FDA expanded the indication for Tremfya (guselkumab) to children with plaque psoriasis or active psoriatic ...

For years, managing active psoriatic arthritis (PsA) has been a race against time, with irreversible joint damage and long-term disability often the heartbreaking end-point for patients. Now, a major ...